Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) represent injectable therapies for the treatment of type 2 diabetes and provide significant weight loss, resulting from appetite control, increased satiety, and delayed gastric emptying [146]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.